Curocell

Curocell EPS

The Earnings per Share (EPS) of Curocell (372320.KQ) as of Oct 27, 2026 is -3,073.95 KRW. In the previous year, Earnings per Share (EPS) was -2,693.04 KRW — a change of 14.14% (lower).

EPS

-3,073.95KRW

YoY

14.14%

Last updated:

Earnings per Share (EPS) of Curocell is 2025 -3,073.95 KRW. Earnings per Share (EPS) of Curocell was 2024 -2,693.04 KRW. It decreases by 14.14% lower compared to the previous year.

The Curocell EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2021
-3,935.70 KRW
Jan 1, 2022
-2,856.52 KRW
Jan 1, 2023
-2,172.59 KRW
Jan 1, 2024
-2,693.04 KRW
Jan 1, 2025
-3,073.95 KRW
The Curocell EPS history
YEAREPSYoY
-3,073.95KRW+14.14%
-2,693.04KRW+23.96%
-2,172.59KRW-23.94%
-2,856.52KRW-27.42%
-3,935.70KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

Earnings per Share (EPS) of Curocell is -3,073.95 KRW in 2025.

Earnings per Share (EPS) of Curocell changed from -2,693.04 KRW to -3,073.95 KRW, representing a 14.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Curocell since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Curocell

All Key Metrics — Curocell